TTM: Hypothermia after cardiac arrest does not offer benefits

Previous studies evaluated therapeutic hypothermia (32 ° C to 34 ° C for 12-24 hours) in patients who remain unconscious after resuscitation from cardiac arrest showing improvement in neurological recovery and survived. However, the ideal temperature is not set. 

This study enrolled 950 patients in 36 centers in Europe and Australia and randomized to hypothermia (33 ° C) or normothermia. The primary end point was death from all causes and the secondary a combination of death and neurological dysfunction at 180 days. The primary end point occurred in 50 % of the hypothermia group and 48 % in the normothermia group (HR 1.06 , 95% CI 0.89 to 1.28 , P = .51 ) . The results for the secondary end point were also similar.

Conclusion:

In unaware survivors of cardiac arrest outside hospital, hypothermia at a temperature of 33 ° C does not provide benefits versus normothermia.

Original article


Niklas Nielsen
2013-11-17

Original title: TTM trial: Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest

More articles by this author

Mild hypothermia in pre-hospital phase after cardiac arrest

Hypothermia in the hospital phase at 32-34 ° C improves neurological outcome in patients resuscitated after ventricular fibrillation out of the hospital environment. In...

NIAMI: Nitroprusside infusion prior to primary angioplasty

The phenomenon of reperfusion injury is responsible for 50 % of the final infarct size. Several pharmacological and non-pharmacological agents administered before or during...

CATIS: Immediate reduction in blood pressure demonstrated no benefit in acute stroke

It is shown that hypertension is associated with the occurrence of stroke but immediate treatment for an acute stroke itself is unclear. This study...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...